Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients

Overview

Journal J Pers Med

Date 2022 Dec 29

PMID 36579506

Authors

Zaira Maraia

Tony Mazzoni

Marco Bruno Luigi Rocchi

Denise Feliciani

Maria Chiara Romani

Giovanna Acciarri

Stefania Rafaiani

Isidoro Mazzoni

Affiliations

Soon will be listed here.

Abstract

Methods: All patients with RA, Psoriasis and IBD were included in this observational analysis and treated with anti-TNFα, IL-inhibitors, Methotrexate (MTX) and Sulfasalazine drugs during the year 2020-2021. The population consisted of 932 patients and demographic, clinical and pharmacological data were analyzed.

Results: Although no significant differences were observed between patients treated with biological and synthetic drugs in terms of hospitalization and death, the multivariate logistic model showed that the type of drug influences the possibility of COVID-19 positivity.

Conclusions: The results of this analysis support the use of biological drugs and justify further research investigating the association of these biological therapies with COVID-19 outcomes.

References

Robinson P, Liew D, Liew J, Monaco C, Richards D, Shivakumar S . The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med. 2020; 1(1):90-102. PMC: 7713589. DOI: 10.1016/j.medj.2020.11.005. View

Schinocca C, Rizzo C, Fasano S, Grasso G, Barbera L, Ciccia F . Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Front Immunol. 2021; 12:637829. PMC: 7937623. DOI: 10.3389/fimmu.2021.637829. View

Fisher B, Veenith T, Slade D, Gaskell C, Rowland M, Whitehouse T . Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir Med. 2021; 10(3):255-266. PMC: 8676420. DOI: 10.1016/S2213-2600(21)00460-4. View

Ruiz de Morales J, Puig L, Dauden E, Canete J, Pablos J, Olveira Martin A . Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2019; 19(1):102429. DOI: 10.1016/j.autrev.2019.102429. View

Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z . Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020; 12(13):12493-12503. PMC: 7377860. DOI: 10.18632/aging.103579. View

Charles P, Elliott M, Davis D, Potter A, Kalden J, Antoni C . Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999; 163(3):1521-8. View

Brenner E, Ungaro R, Gearry R, Kaplan G, Kissous-Hunt M, Lewis J . Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020; 159(2):481-491.e3. PMC: 7233252. DOI: 10.1053/j.gastro.2020.05.032. View

Lee S, Kwon J, Cho M . Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018; 16(1):26-42. PMC: 5797268. DOI: 10.5217/ir.2018.16.1.26. View

Jang D, Lee A, Shin H, Song H, Park J, Kang T . The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci. 2021; 22(5). PMC: 7962638. DOI: 10.3390/ijms22052719. View

10.

Berardicurti O, Ruscitti P, Ursini F, DAndrea S, Ciaffi J, Meliconi R . Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. Clin Exp Rheumatol. 2020; 38(6):1247-1254. View

11.

Rendon A, Schakel K . Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6). PMC: 6471628. DOI: 10.3390/ijms20061475. View

12.

Patel S, Wadhwa M . Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomed Pharmacother. 2021; 140:111785. PMC: 8162906. DOI: 10.1016/j.biopha.2021.111785. View

13.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

14.

Dewanjee S, Kandimalla R, Kalra R, Valupadas C, Vallamkondu J, Kolli V . COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges. Cells. 2021; 10(12). PMC: 8699554. DOI: 10.3390/cells10123291. View

15.

Schett G, Manger B, Simon D, Caporali R . COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020; 16(8):465-470. PMC: 7304381. DOI: 10.1038/s41584-020-0451-z. View

16.

Teich N, Ludewig C, Schmelz R, Bastlein E, Geissler S, Nagl S . [Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease]. Z Gastroenterol. 2021; 59(11):1189-1196. DOI: 10.1055/a-1508-6734. View

17.

Faqihi F, Alharthy A, Memish Z, Karakitsos D . Comment on Hu et al: The cytokine storm and COVID-19. J Med Virol. 2020; 93(2):631-633. PMC: 7436490. DOI: 10.1002/jmv.26396. View

18.

Azkur A, Akdis M, Azkur D, Sokolowska M, Veen W, Bruggen M . Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020; 75(7):1564-1581. PMC: 7272948. DOI: 10.1111/all.14364. View

19.

Vignali D, Kuchroo V . IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012; 13(8):722-8. PMC: 4158817. DOI: 10.1038/ni.2366. View

20.

Araki Y, Mimura T . The Mechanisms Underlying Chronic Inflammation in Rheumatoid Arthritis from the Perspective of the Epigenetic Landscape. J Immunol Res. 2017; 2016:6290682. PMC: 5225373. DOI: 10.1155/2016/6290682. View